Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 255 participants.
Also called NCT03230786
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 255 participants
- Sponsor
- KeyBioscience AG
- Registry
-
NCT03230786 -
2017-001061-24
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Czechia, Denmark, Moldova, Poland, Romania, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03230786. Randomized; triple masking; primary purpose treatment. Start 2017-08-23 (actual); primary completion 2018-07-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Daily injection of KBP/placebo for 12 weeks as add-on to metformin
- Lead sponsor
- KeyBioscience AG
- Collaborator
- Nordic Bioscience A/S
Record details
- Record id
cardio:ct-nct03230786- Content hash
473e2af512d76e4eb80e0b85e64d2bd653a0507cc7d2d2a2e25df395240d9f91